Standigm had participated in the AstraZeneca-Sanger Drug Combination Prediction Dream Challenge hosted by one of the leading pharmaceutical companies, AstraZeneca. Standigm team ranked third among 71 international teams. Standigm will apply the methods to precision medicine, patient stratification, and therapeutic/diagnostic design.
Seoul, Korea, South, February 05, 2016- On February 4th, Standigm, an artificial intelligence and systems biology-based startup, announced that it attracted approximately $250 K (300 million won) worth of investment from K Cube Ventures (CEO Seng Woon Yoo). Aside from K Cube Ventures’ investment, Standigm has earned support from Tech Incubator Program For Startup (TIPS) and Ministry of Science supported K-Global market friendly SW R&D, securing a total capital of $1.1 million.